Date: 2015-09-02
Type of information: Collaboration agreement
Compound:
Company: Evotec (Germany) CHDI Foundation (USA - NY)
Therapeutic area: Genetic diseases - Neurodegenerative diseases - Rare diseases
Type agreement: collaboration
Action mechanism:
Disease: Huntington’s disease
Details: * On September 11, 2014, Evotec announced that CHDI Foundation has extended and restated its collaboration with Evotec through 2017. The collaboration—which aims to find new treatments for Huntington’s disease, an inherited neurodegenerative disorder—means that CHDI will fund up to 52 full-tie scientists at Evotec over the next three years. The collaboration initially began in 2006 and has expanded considerably over this period to fully leverage Evotec’s integrated neuroscience platform. The restated extension of this collaboration is a further validation of Evotec’s broad drug discovery expertise in the field of neuroscience and includes an expansion to utilise Evotec’s high-throughput screening and proteomics platforms. Evotec provides a full range of research activities and expertise in the neuroscience area to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production.
Financial terms:
Latest news: * On September 2, 2015, Evotec announced that CHDI Foundation has extended and expanded its collaboration with Evotec through to August 2018. Over this period CHDI will fund 55 full-time scientists at Evotec. The collaboration—which aims to find new treatments for Huntington’s disease, will take advantage of additional technologies, capabilities and capacities at Evotec’s facilities in Toulouse, France, and Princeton, NJ, USA.
